HK Stock MarketDetailed Quotes

02359 WUXI APPTEC

Watchlist
  • 51.350
  • -0.800-1.53%
Market Closed Dec 4 16:08 CST
148.30BMarket Cap14.62P/E (TTM)

About WUXI APPTEC Company

The company provides global partners with a full range of new drug development and production services, covering all aspects of new drug research and development, so that anyone and any company can realize their dream of innovation through our enabling platform. We are committed to lowering the R&D threshold, improving R&D efficiency, promoting the early introduction of more new drugs and good drugs, and benefiting patients around the world through integrated and open capabilities and technology platforms. The company's main business can be divided into five major segments: chemical business (wuxiTesting), biology business (wuxiBiology), cell and gene therapy CTDMO business (wuxiTU), and domestic new drug development service department (wuxiDSU). The scope of services covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions. Company honors include Baihua Association's “Enterprise of the Year Award”, Sina Pharmaceuticals's “Most Influential Enterprise in China's Pharmaceutical Industry”, and “China's 100 Model Employers” for four consecutive years.

Company Profile

Symbol02359
Company NameWUXI APPTEC
ISINCNE100003F19
Listing DateDec 13, 2018
Issue Price68.00
Shares Offered116.47M share(s)
FoundedDec 1, 2000
Registered AddressChina
Chairmange li
Secretaryyuefenzhangyuanzhou zhang
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficeMashan No. 5 Bridge, Binhu District, Wuxi City, Jiangsu Province
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees38134
MarketHong Kong motherboard
Phone86-21-20663091
Fax86-21-50463093
Emailir@wuxiapptec.com
BusinessDevelopment, research and approval of new drugs, pharmaceutical intermediates and fine chemical products (excluding dangerous chemicals); technology development, technology transfer, technical services and technical consulting for pharmaceutical technology, biotechnology, combinatorial chemistry, organic chemistry, medical technology, testing technology, computer technology; wholesale of first-class medical devices and pharmaceuticals, sales of machinery, equipment and spare parts; independent operation and agency of import and export business of various types of goods and technologies (excluding goods and technologies restricted by the country or prohibited from being imported and exported); enterprise management consulting, medical information consulting, health consulting (excluding diagnosis and treatment activities, psychological counseling) ; Housing leasing; Conference and exhibition services; Outbound investment using own funds. (For projects requiring approval according to law, business activities can only be carried out after approval by the relevant departments) (In the end, industrial and commercial approval shall prevail)

Company Executives

  • Name
  • Position
  • Salary
  • ge li
  • Chairman, Executive Director, Contact the CEO, Chairman of the Strategy Committee, Nomination Committee Members
  • 61.93M
  • minzhang chen
  • Executive Director, Co-CEO
  • 24.93M
  • zhengguo hu
  • Vice Chairman, Executive Director, Chief Investment Officer, Strategy Committee Members, Authorized Representative
  • 17.75M
  • qing yang
  • Executive Director, Co-CEO
  • 17.52M
  • chaohui zhang
  • VP, Executive Director, Chief Operating Officer
  • 12.43M
  • xiaomeng tong
  • Non-executive Directors, Strategy Committee Members
  • --
  • yibing wu
  • Non-executive Directors, Strategy Committee Members
  • --
  • shaohua lu
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • 233.00K
  • wei yu
  • Independent Non-Executive Director, Strategy Committee Members, Audit Committee Members
  • 233.00K
  • xin zhang
  • Independent Non-Executive Director, Audit Committee Members, Member of the Remuneration and Assessment Committee
  • 233.00K
  • zhiling zhan
  • Independent Non-Executive Director, Chairman of the Remuneration and Assessment Committee, Nomination Committee Members
  • 233.00K
  • dai feng
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
  • 400.00K
  • liang he
  • Chairman of the Supervisory Board, Shareholders' Representatives and Supervisors
  • --
  • baiyang wu
  • Auditors
  • --
  • minfang zhu
  • Employee Representative Supervisor
  • --
  • ming shi
  • Chief Financial Officer
  • --
  • shuhui chen
  • Company Advisors
  • --
  • yuanzhou zhang
  • Joint Company Secretary, Authorized Representative
  • --
  • yuefen zhang
  • Joint Company Secretary, Authorized Representative
  • --